Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Shorted: Short Interest Up 47.4% in October

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 4,556,267 shares, a growth of 47.4% from the October 15th total of 3,090,758 shares. Approximately 7.0% of the company’s stock are short sold. Based on an average daily trading volume, of 6,864,487 shares, the short-interest ratio is currently 0.7 days.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS traded down $0.01 during midday trading on Tuesday, reaching $0.21. 1,024,850 shares of the stock were exchanged, compared to its average volume of 1,173,056. The company has a market cap of $15.19 million, a P/E ratio of -0.13 and a beta of 0.51. The stock’s 50 day simple moving average is $1.79 and its 200 day simple moving average is $2.39. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.17. Acumen Pharmaceuticals has a twelve month low of $0.19 and a twelve month high of $3.60.

Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last announced its quarterly earnings results on Monday, October 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts expect that Acumen Pharmaceuticals will post -1.50 earnings per share for the current year.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC bought a new position in shares of Acumen Pharmaceuticals in the 2nd quarter worth approximately $5,637,000. BlackRock Inc. bought a new stake in Acumen Pharmaceuticals during the second quarter valued at approximately $6,649,000. Bank of America Corp DE bought a new stake in Acumen Pharmaceuticals during the second quarter valued at approximately $734,000. Spark Investment Management LLC bought a new stake in Acumen Pharmaceuticals during the second quarter valued at approximately $39,000. Finally, Two Sigma Securities LLC bought a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at $32,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Analyst Upgrades and Downgrades

ABOS has been the subject of a number of research reports. Stifel Nicolaus downgraded shares of Acumen Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Friday, October 30th. Weiss Ratings upgraded Acumen Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Lucid Cap Mkts cut Acumen Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 17th. Finally, BTIG Research reduced their target price on shares of Acumen Pharmaceuticals to $1.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $1.00.

View Our Latest Research Report on ABOS

About Acumen Pharmaceuticals

(Get Free Report)

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease. The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.

See Also

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.